160th ANNUAL MEETING OF THE AOS
May 16-18, 2024
The Lodge at Torrey Pines
La Jolla, California
This activity is jointly provided by Medical Education Resources (MER) and the American Ophthalmological Society (AOS).
PROGRAM OVERVIEW
The AOS Annual Meeting provides interactive educational platform for attendees. Attendees are provided the opportunity to learn about up-to-date technology and ophthalmic tools and equipment, as well as learn about the latest research and findings across all subspecialties. The meeting will promote excellence in patient care, education, and research, and address essential issues in medicine, advancing the art and science of ophthalmology.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of ophthalmologists across all subspecialties involved in clinical or surgical eye care, academic, and leadership who are actively involved in or previously cared for patients.
EDUCATIONAL MEETING OBJECTIVES
The objectives of the 2024 Annual Meeting are to:
FACULTY & PROGRAM AGENDA
A complete faculty listing and a detailed program agenda are available in the AOS 2024 Program Book.
FEE INFORMATION
The meeting registration fee for AOS members and Professional Guests is $600. The registration fee for Professional Guests that are residents or fellows is $300.
ACCREDITATION STATMENT
In support of improving patient care, this activity has been planned and implemented by MER and the AOS. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT
MER designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
MER ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
Relevant financial relationships of all presenting authors, staff, and members of the Committee on Programs are listed in the program book. If the presenter has a financial relationship related to the specific presentation, the disclosure will be stated verbally and presented on the first slide of their presentation. Audience participants are required to state their financial disclosure before they join a discussion of a paper or poster.
DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of MER or the AOS. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.